Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 6 (2), 74-7

The Prostate Health Index: A New Test for the Detection of Prostate Cancer


The Prostate Health Index: A New Test for the Detection of Prostate Cancer

Stacy Loeb et al. Ther Adv Urol.


A major focus in urologic research is the identification of new biomarkers with improved specificity for clinically-significant prostate cancer. A promising new test based on prostate-specific antigen (PSA) is called the Prostate Health Index (PHI), which has recently been approved in the United States, Europe and Australia. PHI is a mathematical formula that combines total PSA, free PSA and [-2] proPSA. Numerous international studies have consistently shown that PHI outperforms its individual components for the prediction of overall and high-grade prostate cancer on biopsy. PHI also predicts the likelihood of progression during active surveillance, providing another noninvasive modality to potentially select and monitor this patient population. This article reviews the evidence on this new blood test with significant promise for both prostate cancer screening and treatment decision-making.

Keywords: PHI; PSA; free PSA; prognosis; prostate cancer; prostate health index; screening.

Conflict of interest statement

Conflict of interest statement: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Similar articles

See all similar articles

Cited by 32 PubMed Central articles

See all "Cited by" articles